WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Now Available: The U.S. Dredge Report—download today for expert insights, data, and a clear view of the U.S. dredging market.→ Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

199.29 +5.84 (+3.02%)
Streaming Delayed Price Updated: 10:36 AM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates
Via Investor Brand Network
Topics Intellectual Property
News headline image
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
From Biogen Inc.
Via GlobeNewswire
News headline image
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
From BioMedWire
Via GlobeNewswire
News headline image
Spotlight Movers: APLS, VTIX, ELAB, ARTL Fuel Multi-Sector Momentum
Via AB Newswire
News headline image
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
From Biogen Inc.
Via GlobeNewswire
News headline image
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Announces Board Chair Transition
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair 
From Biogen Inc.
Via GlobeNewswire
News headline image
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
From Biogen Inc.
Via GlobeNewswire
News headline image
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Completes Acquisition of Alcyone Therapeutics
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
From Biogen Inc.
Via GlobeNewswire
News headline image
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.